The research question
Which eligibility rules, visit requirements and study tasks are likely to limit participation?
Proposed design
Protocol review plus opt-in screening and participation interviews. Any referral pilot is agreed with the receiving study site.
Illustrative design: a scoped screening pilot and one interview per participant; setup and recruitment are scoped separately.
Data to collect
- Screening completion and exclusion reasons
- Availability and travel constraints
- Digital-access and language needs
- Willingness to complete proposed tasks
Planned outputs
- Feasibility counts with clearly defined denominators
- Recruitment and participation barriers
- Protocol-burden recommendations
What we confirm with you
We agree the population, sample size, country, collection tools, analysis plan and budget. Collection starts after the required consent, ethics or other permissions and a signed scope are in place.
- Secure consent before recontact or sharing participant details
- Keep final clinical eligibility with the study investigator
- Confirm active study status, geography and recruitment permission
Clinical records, laboratory results, photographs and device integrations are included only when access, collection quality and permitted use have been verified. Self-reported findings are identified as such.
Research context
These published sources explain the research need or method. They are not RIDLY customers, endorsements or purchase commitments.
- FDA guidance on decentralized trial elements
Remote study activities are an established design option; investigator oversight and participant support still matter.
- FDA guidance on representative patient input
Sampling and participant characteristics affect how patient experience findings can be interpreted.
Related dataset profiles
For an existing-data inquiry, start with a coverage review.